Mga Batayang Estadistika
| CIK | 1851194 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ventyx Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
Amended and Restated Outside Director Compensation Policy, adopted April 3, 2025. Exhibit 10.1 VENTYX BIOSCIENCES, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Effective as of April 3, 2025 (the “Effective Date”) Ventyx Biosciences, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Dire |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| August 7, 2025 |
Exhibit 99.1 Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress • Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease • Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 • Phase 2 study of VTX3232 in participant |
|
| August 7, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 17, 2025 |
Exhibit 99.1 Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease CSF and plasma exposures reinforce VTX3232’s potential as a once-daily oral therapy for neu |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 10, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 04, 2025 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| May 8, 2025 |
Exhibit 99.1 Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and ca |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 23, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. |
|
| February 28, 2025 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common S |
|
| February 27, 2025 |
Exhibit 10.7 May 14, 2021 Sheila Gujrathi [***] Dear Sheila, On behalf of Ventyx Biosciences, Inc. (the “Company”), I am extremely pleased to invite you to join the Company as Executive Chairperson of the Company through the ninetieth (90th) day following the closing of the Company’s IPO (as defined below) (“Executive Chairperson”) and as a member of the Company’s board of directors (the “Board”), |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 27, 2025 |
Exhibit 19.1 VENTYX BIOSCIENCES, INC. INSIDER TRADING POLICY (Effective as of October 20, 2021; as amended on December 6, 2021, April 6, 2023, and April 18, 2024) A. POLICY OVERVIEW Ventyx Biosciences, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations |
|
| February 27, 2025 |
Exhibit 99.1 Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress Topline data readouts from multiple Phase 2 studies expected throughout 2025 • VTX2735 in patients with recurrent pericarditis in H2 • VTX3232 in participants with obesity and cardiometabolic risk factors in H2 • VTX3232 biomarker study in patients with early Parkins |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| February 13, 2025 |
EX-99.A 2 e664192ex99-a.htm Exhibit A Joint Filing Agreement The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Ventyx Biosciences, Inc. shall be filed on behalf of the undersigned. DEERFIELD MGMT, L.P. By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact DEERFIELD MANAGEMENT COMPANY, L.P. By: Fl |
|
| February 13, 2025 |
EX-99.B 3 e664192ex99-b.htm Exhibit B Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934. |
|
| January 29, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p25-0331exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of fi |
|
| January 14, 2025 |
EX-99.1 Exhibit 99.1 Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with recurrent pericarditis expected to initiate in January, with topl |
|
| January 14, 2025 |
EX-99.2 Exhibit 99.2 CORPORATE PRESENTATION January 2025 Forward Looking Statements Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction (Commission (IRS Employer o |
|
| November 15, 2024 |
Ventyx Biosciences, Inc. 7,060,100 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-283076 PROSPECTUS Ventyx Biosciences, Inc. 7,060,100 Shares of Common Stock This prospectus covers the offer and resale from time to time of up to 7,060,100 shares of our common stock, par value $0.0001 per share, issuable upon conversion of 70,601 shares of Series A Non-Voting Convertible Preferred Stock (“Series A Preferred |
|
| November 14, 2024 |
VTYX / Ventyx Biosciences, Inc. / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
VTYX / Ventyx Biosciences, Inc. / Flynn James E Passive Investment SC 13G/A 1 e664012sc13ga-vb.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Ventyx Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92332V107 (CUSIP Number) September 30 |
|
| November 14, 2024 |
SC 13G/A 1 p24-3268sc13ga.htm VENTYX BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stateme |
|
| November 13, 2024 |
November 13, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Alan Campbell Re: Ventyx Biosciences, Inc. (the “Registrant”) Registration Statement on Form S-3 (File No. 333-283076) Request for Acceleration Acceleration Request Requested Date: November 15, 2024 Requested Time: 4:00 |
|
| November 7, 2024 |
Exhibit 99.1 Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors expected to initiate by year-end, with topline results anticipated in H2 2025 Phase 2 |
|
| November 7, 2024 |
Offer Letter, dated July 2, 2024, by and between the Registrant and Mark Forman. Exhibit 10.4 July 2, 2024 Mark Forman, MD, PhD [***] Via electronic mail Re: Employment Letter Dear Mark, This employment letter agreement (the “Agreement”) is entered into between you and Ventyx Biosciences, Inc. (the “Company” or “we”), to set forth the terms and conditions of your employment with the Company. 1. Title; Position. Effective as of August 15, 2024 (the “Effective Date”), you will s |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| November 7, 2024 |
Offer Letter, dated December 1, 2022, by and between the Registrant and Roy Gonzales. Exhibit 10.3 December 1, 2022 Roy Gonzales [***] Dear Roy, On behalf of Ventyx Biosciences, Inc. (the “Company”), I am pleased to set forth the terms of your employment with the Company, should you accept our offer: 1. You will serve as Vice President of Accounting of the Company. You will be responsible for performing such duties and responsibilities as are customary for your position, as well as |
|
| November 7, 2024 |
As filed with the Securities and Exchange Commission on November 7, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 7, 2024 Registration No. |
|
| November 7, 2024 |
Exhibit 10.5 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into as of April 5, 2024, by and between Ventyx Biosciences, Inc., a corporation organized under the laws of Delaware, having a principal place of business at 12790 El Camino Real, Suite 200, San Diego, CA 92130 (the “Company”), and Christopher W. Krueger, an individual with an address at [***] (“Con |
|
| November 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 7, 2024 |
Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Martin D. Auster, M.D. (“Executive”) and Ventyx Biosciences, Inc. (the “Company”) (jointly referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Executive was employed by the Company; WHEREAS, Executive signed a confirmatory employment letter |
|
| November 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ventyx Biosciences, Inc. |
|
| September 23, 2024 |
EX-3.1 Exhibit 3.1 VENTYX BIOSCIENCES, INC. CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW VENTYX BIOSCIENCES, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) do |
|
| September 23, 2024 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 23, 2024, by and between Ventyx Biosciences, Inc., a Delaware corporation (the “Company”), and Aventis Inc., a company organized and existing under the laws of Pennsylvania, having registered offices at 55 Corporate Drive, Bridgewater, New Jersey 08807 (the “Purchaser”) |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commis |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commissio |
|
| August 8, 2024 |
Amended and Restated Outside Director Compensation Policy, adopted April 3, 2024. Exhibit 10.2 VENTYX BIOSCIENCES, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Effective as of April 3, 2024 (the “Effective Date”) Ventyx Biosciences, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Dire |
|
| August 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 8, 2024 |
Exhibit 99.1 Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson’s disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 Mark Forman, MD, PhD will jo |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| June 26, 2024 |
VTYX / Ventyx Biosciences, Inc. / NSV Investments I, L.P. - AMENDMENT NO. 11 Activist Investment SC 13D/A 1 schedule13da.htm AMENDMENT NO. 11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* ——————— VENTYX BIOSCIENCES, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 We |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commission F |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction (Commission (IRS Employer of in |
|
| June 5, 2024 |
EX-99.1 Exhibit 99.1 Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 16, 2024 |
Employment letter between the Company and Mr. Moore, dated May 3, 2024. Exhibit 10.1 May 1, 2024 Matthew Moore [***] [***] Via electronic mail Re: Employment Letter Dear Matthew, This employment letter agreement (the “Agreement”) is entered into between you and Ventyx Biosciences, Inc. (the “Company” or “we”), to set forth the terms and conditions of your employment with the Company. 1. Title; Position. Effective as of May 16, 2024 (the “Effective Date”), you will ser |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| May 9, 2024 |
Exhibit 99.1 Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as of M |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 1, 2024 |
Ventyx Biosciences, Inc. 11,174,000 Shares of Common Stock Offered by the Selling Stockholders Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-278584 PROSPECTUS Ventyx Biosciences, Inc. 11,174,000 Shares of Common Stock Offered by the Selling Stockholders This prospectus covers the offer and resale from time to time of up to 11,174,000 shares of our common stock, par value $0.0001 per share, by the selling stockholders identified in this prospectus, including their t |
|
| April 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 25, 2024 |
April 25, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Chris Edwards Re: Ventyx Biosciences, Inc. (the “Registrant”) Registration Statement on Form S-3 (File No. 333-278584) Request for Acceleration Acceleration Request Requested Date: April 29, 2024 Requested Time: 4:00 PM E |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ventyx Biosciences, Inc. |
|
| April 9, 2024 |
As filed with the Securities and Exchange Commission on April 9, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 9, 2024 Registration No. |
|
| April 5, 2024 |
Consulting Agreement by and between the Company and Christopher Krueger, dated April 5, 2024. Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into as of April 5, 2024, by and between Ventyx Biosciences, Inc., a corporation organized under the laws of Delaware, having a principal place of business at 12790 El Camino Real, Suite 200, San Diego, CA 92130 (the “Company”), and Christopher W. Krueger, an individual with an address at [***] (“Con |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commission |
|
| April 4, 2024 |
VTYX / Ventyx Biosciences, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| March 21, 2024 |
VTYX / Ventyx Biosciences, Inc. / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92332V107 (CUSIP Number) March 11, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| March 21, 2024 |
EX-99.1 2 exhibit99-1.htm Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of March 21, 2024, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a stat |
|
| March 13, 2024 |
VTYX / Ventyx Biosciences, Inc. / NSV Investments I, L.P. - AMENDMENT NO. 10 Activist Investment SC 13D/A 1 schedule13da.htm AMENDMENT NO. 10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* ——————— VENTYX BIOSCIENCES, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 We |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commission |
|
| March 11, 2024 |
Exhibit 99.1 Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson’s disease and obesity in H2 2024 Topline Phase 2 data for VTX2735 in CAPS patients esta |
|
| March 8, 2024 |
VTYX / Ventyx Biosciences, Inc. / NSV Investments I, L.P. - AMENDMENT NO. 9 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* ——————— VENTYX BIOSCIENCES, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 West Putnam Avenue, Suite 400 Greenwich, CT 0683 |
|
| March 7, 2024 |
Form of Registration Rights Agreement, by and among the Company and the Purchasers Exhibit 10.2 FORM OF REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of March 6, 2024 by and among Ventyx Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, the Company and |
|
| March 7, 2024 |
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock Exhibit 99.1 Ventyx Biosciences Announces $100 Million Private Placement of Common Stock SAN DIEGO, Calif., March 7, 2024 (GLOBE NEWSWIRE) – Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, announced today that it has entered int |
|
| March 7, 2024 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT BY AND BETWEEN VENTYX BIOSCIENCES, INC. AND EACH OF THE PURCHASERS AS SET FORTH HEREIN MARCH 6, 2024 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Common Stock 5 2.1 Purchase and Sale 5 2.2 Closing 5 3. Representations and Warranties of the Company 6 3.1 Organization and Power 6 3.2 Capitalization 6 3.3 Registration Rights 7 3.4 Authorization 7 3. |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February February 27, 2024 POS AM Table of Contents As filed with the Securities and Exchange Commission on February February 27, 2024 Registration No. |
|
| February 27, 2024 |
Consulting Agreement, dated November 20, 2023, by and between the Registrant and William J. Sandborn Exhibit 10.23 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into as of November 20, 2023 (the “Effective Date”) by and between Ventyx Biosciences, Inc., a corporation organized under the laws of Delaware, having a principal place of business at 12790 El Camino Real, Suite 200, San Diego, CA 92130 (the “Company”) (together with any Company Affiliate, the “Com |
|
| February 27, 2024 |
Exhibit 97.1 VENTYX BIOSCIENCES, INC. COMPENSATION RECOVERY POLICY As adopted on October 26, 2023 Ventyx Biosciences, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay- |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 27, 2024 |
Exhibit 99.1 Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress Ventyx to host virtual investor event on March 11th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis Cash, cash equivalents and marketable securities of $252.2 million as of Decembe |
|
| February 27, 2024 |
Exhibit 10.22 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between William J. Sandborn, M.D. (“Employee”) and Ventyx Biosciences, Inc. (the “Company”) (jointly referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee signed an offer letter with the Company |
|
| February 23, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99 2 p24-1022exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing add |
|
| February 23, 2024 |
SC 13G 1 p24-1022sc13g.htm VENTYX BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) February 22, 2024 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 14, 2024 |
US92332V1070 / VENTYX BIOSCIENCES INC / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243573d14sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shares” |
|
| February 13, 2024 |
US92332V1070 / VENTYX BIOSCIENCES INC / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv02197-ventyxbiosciencesinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Ventyx Biosciences Inc Title of Class of Securities: Common Stock CUSIP Number: 92332V107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursu |
|
| February 13, 2024 |
Powers of Attorney (included on signature page). Table of Contents As filed with the Securities and Exchange Commission on February 13, 2024 Registration No. |
|
| February 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment to Form S-3 (Form Type) Ventyx Biosciences, Inc. |
|
| February 13, 2024 |
Exhibit 4.7 VENTYX BIOSCIENCES, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishmen |
|
| January 29, 2024 |
US92332V1070 / VENTYX BIOSCIENCES INC / TANG CAPITAL PARTNERS LP Passive Investment SC 13G 1 z123240sc13g.htm Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) January 19, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to des |
|
| January 29, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Ventyx Biosciences, Inc. and further agree to the filing o |
|
| January 2, 2024 |
EX-24.1 Exhibit 24.1 POWER OF ATTORNEY – VENTYX BIOSCIENCES, INC. DIRECTORS KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned directors of VENTYX BIOSCIENCES, INC., a Delaware corporation (the “Company”), hereby nominates and appoints RAJU MOHAN, MARTIN AUSTER and CHRISTOPHER KRUEGER, and each of them acting or signing singly, as such director’s agents and attorneys-in-fact, in his |
|
| January 2, 2024 |
As filed with the Securities and Exchange Commission on January 2, 2024 S-8 As filed with the Securities and Exchange Commission on January 2, 2024 Registration No. |
|
| January 2, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction (Commission (IRS Employer o |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2023 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commiss |
|
| November 9, 2023 |
Exhibit 99.1 Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress Ventyx to provide updates across clinical-stage portfolio in the first quarter of 2024 Cash, cash equivalents and marketable securities of $300.8 million as of September 30, 2023 SAN DIEGO, November 9, 2023 (GLOBE NEWSWIRE) – Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a cl |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| November 9, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commissi |
|
| November 6, 2023 |
Exhibit 99.1 Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16 Efficacy results did not meet the internal target to support further development of |
|
| November 6, 2023 |
Introduction Raju Mohan, Ph.D. Founder and Chief Executive Officer VTX958 Phase 2 Plaque Psoriasis Results November 6, 2023 Exhibit 99.2 Forward Looking Statements Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements |
|
| October 10, 2023 |
Introduction Raju Mohan, Ph.D. Founder and Chief Executive Officer 3 Exhibit 99.2 VTX002 Phase 2 Ulcerative Colitis Results October 9, 2023 1 Forward Looking Statements Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statemen |
|
| October 10, 2023 |
Exhibit 99.1 Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis VTX002 60 mg achieved the primary endpoint of clinical remission with a high rate of complete endoscopic remission Both 30 mg and 60 mg doses of VTX002 demonstrated an excellent safety and tolerability profile Ventyx to host conference call and |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2023 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commissio |
|
| August 10, 2023 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VENTYX BIOSCIENCES, INC. a Delaware corporation Ventyx Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A. The Company was originally incorporated under the name of Ventyx Biosciences, Inc., and the original Certificate of Incorporation of |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 10, 2023 |
Exhibit 99.1 Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress Completed enrollment in the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis, with topline readouts expected in Q4 2023 Initiated a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor, |
|
| July 26, 2023 |
Exhibit 10.1 SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (this “Sublease”) is made and entered into this 21st day of July, 2023 (the “Effective Date”), by and between NEUROCRINE BIOSCIENCES, INC., a Delaware corporation (hereinafter referred to as the “Sublandlord”) and VENTYX BIOSCIENCES, INC., a Delaware corporation (hereinafter referred to as the “Subtenant”) (together, the “Parties”). W I T N E |
|
| July 26, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commission |
|
| July 19, 2023 |
US92332V1070 / VENTYX BIOSCIENCES INC / NSV Investments I, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* ——————— VENTYX BIOSCIENCES, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 West Putnam Avenue, Suite 400 Greenwich, CT 0683 |
|
| July 11, 2023 |
US92332V1070 / VENTYX BIOSCIENCES INC / NSV Investments I, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* ——————— VENTYX BIOSCIENCES, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 West Putnam Avenue, Suite 400 Greenwich, CT 0683 |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commission F |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| May 11, 2023 |
Amended and Restated Outside Director Compensation Policy. Exhibit 10.1 VENTYX BIOSCIENCES, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Effective as of April 24, 2023 (the “Effective Date”) Ventyx Biosciences, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Dir |
|
| May 11, 2023 |
Exhibit 99.1 Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is progressing, with topline data expect |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 26, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 14, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 7, 2023 |
US92332V1070 / VENTYX BIOSCIENCES INC / NSV Investments I, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* ——————— VENTYX BIOSCIENCES, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 West Putnam Avenue, Suite 400 Greenwich, CT 0683 |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 23, 2023 |
Exhibit 10.3 VENTYX BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ▪ to attract and retain the best available personnel for positions of substantial responsibility, ▪ to provide additional incentive to Employees, Directors and Consultants, and ▪ to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Opti |
|
| March 23, 2023 |
Exhibit 21.1 Ventyx Biosciences, Inc. List of Subsidiaries Name Jurisdiction of Organization Oppilan Pharma, Ltd. United Kingdom Zomagen Biosciences Belgium BV Belgium Zomagen Biosciences Ltd. United Kingdom |
|
| March 23, 2023 |
Exhibit 99.1 Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis (UC) is on track |
|
| March 23, 2023 |
Exhibit 10.16 VENTYX BIOSCIENCES, INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. 2.1 “Actual Award” means as to any Performance Period, the actual award (if any) payable |
|
| March 23, 2023 |
Outside Director Compensation Policy. Exhibit 10.20 VENTYX BIOSCIENCES, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved September 29, 2021, and effective as of the Effective Date Ventyx Biosciences, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and rewa |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* ——————— VENTYX BIOSCIENCES, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 West Putnam Avenue, Suite 400 Greenwich, CT 0683 |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* ——————— VENTYX BIOSCIENCES, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 West Putnam Avenue, Suite 400 Greenwich, CT 0683 |
|
| February 14, 2023 |
US92332V1070 / VENTYX BIOSCIENCES INC / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 92332V107 |
|
| January 30, 2023 |
SC 13D/A 1 brhc10047258sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San F |
|
| January 26, 2023 |
Exhibit 99.1 Ventyx Biosciences 2023 R&D Day January 26, 2023 1 Forward Looking Statements Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements includ |
|
| January 26, 2023 |
Exhibit 99.2 Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day Phase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohn’s disease and psoriatic arthritis are ongoing with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is on track to complete enr |
|
| January 26, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2023 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 12, 2023 |
EX-99.1 2 d395596dex991.htm EX-99.1 Exhibit 99.1 Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors New directors replace current directors Richard Gaster, M.D., Ph.D., Aaron Royston, M.D., and Jigar Choksey ENCINITAS, Calif., January 12, 2023 (GLOBE NEWSWIRE) – Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutic |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 5, 2023 |
As filed with the Securities and Exchange Commission on January 5, 2023 S-8 1 d426284ds8.htm S-8 As filed with the Securities and Exchange Commission on January 5, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 83-2996852 (State or other jurisdiction of incorporatio |
|
| January 5, 2023 |
EX-FILING FEES 4 d426284dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Am |
|
| December 30, 2022 |
US92332V1070 / VENTYX BIOSCIENCES INC / NSV Investments I, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ??????? VENTYX BIOSCIENCES, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 West Putnam Avenue, Suite 400 Greenwich, CT 0683 |
|
| December 20, 2022 |
EX-1.2 2 d601343dex12.htm EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM December 20, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Ventyx Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agen |
|
| December 20, 2022 |
As filed with the Securities and Exchange Commission on December 20, 2022 POS AM 1 d601359dposam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on December 20, 2022 Registration No. 333-267626 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ventyx Biosciences, Inc. (Exact name of registrant as specified |
|
| December 20, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 20, 2022 |
As filed with the Securities and Exchange Commission on December 20, 2022 S-3ASR 1 d601343ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on December 20, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 88-2996852 (State or other |
|
| December 20, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ventyx Biosciences, Inc. |
|
| December 16, 2022 |
US92332V1070 / VENTYX BIOSCIENCES INC / NSV Investments I, L.P. Activist Investment SC 13D/A 1 schedule13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ——————— VENTYX BIOSCIENCES, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 West Putnam Avenue, |
|
| December 15, 2022 |
Exhibit 99.5 SCHEDULE OF TRANSACTIONS The following table sets forth all transactions in the Common Stock effected by the Reporting Persons during the sixty days prior to the filing of this Amendment No. 2. Name Date of Transaction Transaction Amount of Securities Price Fund III 11/23/2022 Sell 84,316 $27.9124 (1) Fund III 11/29/2022 Sell 415,684 $26.6310 (2) Fund III 12/13/2022 Sell 674,741 $34.4 |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Ad |
|
| December 12, 2022 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF VENTYX BIOSCIENCES, INC. (initially adopted on November 21, 2018) (as amended on September 29, 2021 and December 12, 2022) TABLE OF CONTENTS Page ARTICLE I?CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II?MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 30, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 30, 2022 |
Exhibit 99.1 Corporate Presentation December 2022 1 Forward-Looking Statements Ventyx Biosciences, Inc. (?we,? ?us,? ?our,? ?Ventyx,? or the ?Company?) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company?s current beliefs and expectations. Such forward-looking statement |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92332V107 (CUSIP Number) Joshua L. Targoff Third Point LLC 55 Hudson Yards New York, NY 10001 (212) 715-3880 (Name, Address and Telephone N |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| November 3, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 3, 2022 |
Exhibit 99.1 Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress We are on track to initiate Phase 2 trials of our allosteric TYK2 inhibitor VTX958 in psoriasis, Crohn?s disease and psoriatic arthritis this quarter Cash, cash equivalents and marketable securities of $412.4 million as of September 30, 2022, including proceeds from recent private |
|
| October 5, 2022 |
5,350,000 Shares of Common Stock Filed pursuant to Rule 424(b) (3) Registration No: 333-267626 PROSPECTUS 5,350,000 Shares of Common Stock This prospectus covers the offer and resale from time to time of up to 5,350,000 shares of common stock, par value $0. |
|
| September 30, 2022 |
September 30, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Dillon Hagius Re: Ventyx Biosciences, Inc. (the ?Registrant?) Registration Statement on Form S-1 (File No. 333-267626) Request for Acceleration Acceleration Request Requested Date: October 4, 2022 Requested Time: 4:00 P |
|
| September 27, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Ventyx Biosciences, Inc. |
|
| September 27, 2022 |
Exhibit 21.1 Ventyx Biosciences, Inc. List of Subsidiaries Name Jurisdiction of Organization Oppilan Pharma, Ltd. United Kingdom Zomagen Biosciences Belgium BV Belgium Zomagen Biosciences Ltd. United Kingdom |
|
| September 27, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on September 26, 2022. |
|
| September 21, 2022 |
US92332V1070 / VENTYX BIOSCIENCES INC / NSV Investments I, L.P. Activist Investment SC 13D/A 1 schedule13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ventyx Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 West Putnam Avenue, Suite 400 Greenw |
|
| September 19, 2022 |
Exhibit 10.1 EXECUTION COPY STOCK PURCHASE AGREEMENT BY AND BETWEEN VENTYX BIOSCIENCES, INC., AND EACH OF THE PURCHASERS AS SET FORTH HEREIN SEPTEMBER 17, 2022 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Common Stock 5 2.1 Purchase and Sale 5 2.2 Closing 5 3. Representations and Warranties of the Company 5 3.1 Organization and Power 5 3.2 Capitalization 6 3.3 Registration Rights 6 3 |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2022 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 19, 2022 |
VENTYX BIOSCIENCES ANNOUNCES $176.6 MILLION PRIVATE PLACEMENT OF COMMON STOCK Exhibit 99.1 VENTYX BIOSCIENCES ANNOUNCES $176.6 MILLION PRIVATE PLACEMENT OF COMMON STOCK SEPTEMBER 19, 2022 ENCINITAS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) ? Ventyx Biosciences, Inc. (Nasdaq: VTYX) (?Ventyx?), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, announced today t |
|
| September 19, 2022 |
Exhibit 10.2 EXECUTION COPY FORM OF REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the ?Agreement?) is made as of September 17, 2022 by and among Ventyx Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), and the several purchasers signatory hereto (each, a ?Purchaser? and collectively, the ?Purchasers?). RECITALS WHER |
|
| September 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Address and Tele |
|
| August 15, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 15, 2022 |
Exhibit 99.1 Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress VTX958, our allosteric TYK2 inhibitor, demonstrated an excellent safety profile and class-leading target coverage in Phase 1 trial Cash, cash equivalents and marketable securities of $258.4 million as of June 30, 2022, expected to support operations into the first half of 2024 Ven |
|
| August 15, 2022 |
Exhibit 10.1 STANDARD MULTI-TENANT OFFICE LEASE - GROSS 1. Basic Provisions ("Basic Provisions"). 1.1 Parties: This Lease ("Lease"), dated for reference purposes only April 25, 2022, is made by and between Charlotta Partners, Inc., a CA corporation and 9310 Towne Centre Drive Harrison-1, LLC, a CA limited liability company (collectively "Lessor") and Ventyx Biosciences, Inc., a Delaware corporatio |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| June 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commission |
|
| June 29, 2022 |
Exhibit 99.1 Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735 Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1b release assay Phase 2 trial planned in CAPS patients to efficiently establish clinical proof of concept Clinical update in Q3 from Phase 1 trial of VTX958, o |
|
| June 29, 2022 |
CORPORATE PRESENTATION June 29, 2022 Exhibit 99.2 Forward Looking Statements Ventyx cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company?s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: clinical de |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commission F |
|
| May 12, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| May 12, 2022 |
Exhibit 99.1 Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our selective NLRP3 inhibitor, VTX2735, expected in Q2 2022 Announced the appointment of William Sandborn, MD, as President and Chief Medical Officer, strengthening ou |
|
| May 9, 2022 |
Exhibit 99.1 Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer Dr. Sandborn brings a wealth of clinical experience and knowledge to Ventyx as we advance our clinical-stage pipeline of novel oral therapies for patients with inflammatory diseases ENCINITAS, Calif., May 9, 2022 (GLOBE NEWSWIRE) ? Ventyx Biosciences, Inc. (Nasdaq: VTYX), (?Ventyx? |
|
| May 9, 2022 |
EX-10.1 2 d285541dex101.htm EX-10.1 Exhibit 10.1 May 5, 2022 William J. Sandborn, M.D. c/o Ventyx Biosciences, Inc. Re: Employment Letter Dear Bill: This employment letter agreement (the “Agreement”) is entered into between you and Ventyx Biosciences, Inc. (the “Company” or “we”), to set forth the terms and conditions of your employment with the Company. 1. Title; Position. Effective as of May 9, |
|
| May 9, 2022 |
Exhibit 10.2 VENTYX BIOSCIENCES, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION 1. Introduction. The purpose of this Ventyx Biosciences, Inc. Executive Change in Control and Severance Plan (the ?Plan?) is to provide assurances of specified benefits to certain employees of the Company whose employment could be being involuntarily terminated other than for death, Di |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 27, 2022 |
DEF 14A 1 d313295ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 24, 2022 |
Exhibit 10.15 EXECUTIVE CHAIRPERSON SERVICES AGREEMENT This Executive Chairperson Services Agreement (this ?Agreement?) is made as of May 14, 2021 (the ?Effective Date?), by and between Ventyx Biosciences, Inc., a Delaware corporation (the ?Company?), and Sheila Gujrathi (the ?Executive?). R E C I T A L S: WHEREAS, the Company desires that Executive provide Executive Chairperson services to the Co |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40928 Ventyx Biosciences, Inc. |
|
| March 24, 2022 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 23, 2022, Ventyx Biosciences, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act 0f 1934, as amended (the ?Exchange Act?) ? our common stock, par value $0.0001 per share (?common stock?). Description of Common Stock The |
|
| March 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 23, 2022 |
Exhibit 99.1 Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our oral, selective NLRP3 inhibitor, VTX2735, expected in Q2 2022 Phase 2 trial of our S1P1R modulator, VTX002, continues to enroll in ulcerative colitis (UC) Strong cash |
|
| March 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commission |
|
| March 15, 2022 |
Exhibit 99.1 CORPORATE PRESENTATION FIRST QUARTER 2022 Forward Looking Statements Ventyx cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on Ventyx?s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: management? |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the ?Shares?) (Title of Class of Securities) 92332V107 |
|
| November 30, 2021 |
Exhibit 99.1 Corporate Presentation Fourth Quarter 2021 PAGE 1 Forward Looking Statements Ventyx cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company?s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding |
|
| November 30, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2021 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commiss |
|
| November 18, 2021 |
Exhibit 10.2 VENTYX BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Stock Opti |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40298 Ventyx Biosciences, Inc. |
|
| November 18, 2021 |
2019 Equity Incentive Plan, as amended, and forms of agreement thereunder. Exhibit 10.1 VENTYX BIOSCIENCES, INC. 2019 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Stock Opti |
|
| November 17, 2021 |
Exhibit 99.1 Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update Wholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets Dosing initiated in a multiple-ascending dose (MAD) Phase 1 trial for VTX958, an oral, selective tyrosine kinase type 2 (TYK2) inhibitor, and a Phase 1 trial for VTX2735, an or |
|
| November 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commiss |
|
| November 4, 2021 |
VTYX / Ventyx Biosciences Inc / CITADEL ADVISORS LLC - VENTYX BIOSCIENCES, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. )* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) |
|
| November 4, 2021 |
VTYX / Ventyx Biosciences Inc / Third Point LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92332V107 (CUSIP Number) Joshua L. Targoff Third Point LLC 55 Hudson Yards New York, NY 10001 (212) 715-3880 (Name, Address and Telephone Nu |
|
| November 4, 2021 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| November 4, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Ventyx Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the |
|
| November 4, 2021 |
VTYX / Ventyx Biosciences Inc / venBio Global Strategic Fund III, L.P. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Ventyx Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Address and Telephone |
|
| October 29, 2021 |
VTYX / Ventyx Biosciences Inc / NSV Investments I, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Ventyx Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 92332V107 (CUSIP Number) Somasundaram Subramaniam New Science Ventures 500 West Putnam Avenue, Suite 400 Greenwich, CT 06830 (212) 688-5100 |
|
| October 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40928 83-2996852 (State or other jurisdiction of incorporation) (Commissi |
|
| October 25, 2021 |
Amended and Restated Bylaws of the Registrant. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF VENTYX BIOSCIENCES, INC. (initially adopted on November 21, 2018) (as amended on October 25, 2021; effective as of the closing of the company?s initial public offering) TABLE OF CONTENTS Page ARTICLE I?CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II?MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPEC |
|
| October 25, 2021 |
VENTYX BIOSCIENCES, INC. – IPO CLOSING PRESS RELEASE Exhibit 99.1 VENTYX BIOSCIENCES, INC. ? IPO CLOSING PRESS RELEASE Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares ENCINITAS, Calif., October 25, 2021 ? Ventyx Biosciences, Inc. (Nasdaq: VTYX), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living w |
|
| October 25, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant. EX-3.1 2 d135977dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VENTYX BIOSCIENCES, INC. a Delaware corporation Ventyx Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A. The Company was originally incorporated under the name of Ventyx Biosciences, Inc., and the origina |
|
| October 21, 2021 |
As filed with the Securities and Exchange Commission on October 21, 2021 As filed with the Securities and Exchange Commission on October 21, 2021 Registration No. |
|
| October 21, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-259891 Registration No. 333-260397 PROSPECTUS 9,472,656 Shares Common Stock We are offering 9,472,656 shares of our common stock. This is our initial public offering, and no public market currently exists for our common stock. Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol ?V |
|
| October 20, 2021 |
As filed with the Securities and Exchange Commission on October 20, 2021. As filed with the Securities and Exchange Commission on October 20, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-2996852 (State or other jurisdiction of incorporation or organization) |
|
| October 18, 2021 |
October 18, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 18, 2021 |
October 18, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Li Xiao Jeanne Baker Alan Campbell Celeste Murphy Re: Ventyx Biosciences, Inc. (the ?Registrant?) Registration Statement on Form S-1 (File No. 333-259891) Request for Acceleration Acceleration Request Requested Date: Octo |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Ventyx Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 83-2996852 (State of incorporation or organization) (I.R.S. Employer Identification No.) 662 Encinitas Blvd, |
|
| October 15, 2021 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF VENTYX BIOSCIENCES, INC. (initially adopted on November 21, 2018) (as amended on September 29, 2021; effective as of the closing of the company?s initial public offering) TABLE OF CONTENTS Page ARTICLE I?CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II?MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SP |
|
| October 15, 2021 |
Exhibit 10.11 STANDARD MULTI-TENANT OFFICE LEASE - GROSS 1. Basic Provisions (?Basic Provisions?). 1.1 Parties: This Lease (?Lease?), dated for reference purposes only June 14, 2021, is made by and between Charlotta Partners, Inc. a CA corporation and 9310 Towne Centre Drive Harrison-1, LLC, a CA limited liability company (collectively ?Lessor?) and Ventyx Biosciences, Inc. a CA corporation (colle |
|
| October 15, 2021 |
Exhibit 10.3 VENTYX BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Stock Opti |
|
| October 15, 2021 |
Exhibit 10.4 VENTYX BIOSCIENCES, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an ?employee stock purchase plan? under Code |
|
| October 15, 2021 |
Exhibit 10.8 VENTYX BIOSCIENCES, INC. 662 Encinitas Blvd., Ste. 250 Encinitas, CA 92024 October 7, 2021 Martin Auster, M.D. c/o Ventyx Biosciences, Inc. Re: Confirmatory Employment Letter Dear Marty: This confirmatory employment letter agreement (the ?Agreement?) is entered into between you and Ventyx Biosciences, Inc. (the ?Company? or ?we?), to confirm the current terms and conditions of your em |
|
| October 15, 2021 |
Exhibit 10.5 VENTYX BIOSCIENCES, INC. 662 Encinitas Blvd., Ste. 250 Encinitas, CA 92024 October 7, 2021 Raju Mohan, Ph.D. c/o Ventyx Biosciences, Inc. Re: Confirmatory Employment Letter Dear Raju: This confirmatory employment letter agreement (the ?Agreement?) is entered into between you and Ventyx Biosciences, Inc. (the ?Company? or ?we?), to confirm the current terms and conditions of your emplo |
|
| October 15, 2021 |
Subsidiaries of the Registrant. Exhibit 21.1 Ventyx Biosciences, Inc. List of Subsidiaries Name Jurisdiction of Organization Oppilan Pharma, Ltd. United Kingdom Zomagen Biosciences Belgium BV Belgium Zomagen Biosciences Ltd. United Kingdom |
|
| October 15, 2021 |
Exhibit 10.13 VENTYX BIOSCIENCES, INC. 662 Encinitas Blvd., Ste. 250 Encinitas, CA 92024 October 7, 2021 J?rn Drappa, M.D., Ph.D. c/o Ventyx Biosciences, Inc. Re: Confirmatory Employment Letter Dear J?rn: This confirmatory employment letter agreement (the ?Agreement?) is entered into between you and Ventyx Biosciences, Inc. (the ?Company? or ?we?), to confirm the current terms and conditions of yo |
|
| October 15, 2021 |
Exhibit 10.7 VENTYX BIOSCIENCES, INC. 662 Encinitas Blvd., Ste. 250 Encinitas, CA 92024 October 7, 2021 John Nuss, Ph.D. c/o Ventyx Biosciences, Inc. Re: Confirmatory Employment Letter Dear John: This confirmatory employment letter agreement (the ?Agreement?) is entered into between you and Ventyx Biosciences, Inc. (the ?Company? or ?we?), to confirm the current terms and conditions of your employ |
|
| October 15, 2021 |
EX-4.2 5 d160345dex42.htm EX-4.2 Exhibit 4.2 The Corporation shall furnish without charge to each stockholder who so requests a statement of the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock of the Corporation or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Such request |
|
| October 15, 2021 |
Exhibit 10.6 VENTYX BIOSCIENCES, INC. 662 Encinitas Blvd., Ste. 250 Encinitas, CA 92024 October 7, 2021 Christopher Krueger c/o Ventyx Biosciences, Inc. Re: Confirmatory Employment Letter Dear Chris: This confirmatory employment letter agreement (the ?Agreement?) is entered into between you and Ventyx Biosciences, Inc. (the ?Company? or ?we?), to confirm the current terms and conditions of your em |
|
| October 15, 2021 |
As filed with the Securities and Exchange Commission on October 15, 2021. Table of Contents As filed with the Securities and Exchange Commission on October 15, 2021. |
|
| October 15, 2021 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VENTYX BIOSCIENCES, INC. a Delaware corporation Ventyx Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), does hereby certify as follows: A. The Company was originally incorporated under the name of Ventyx Biosciences, Inc., and the original Certificate of Incorporation of |
|
| October 15, 2021 |
Form of Underwriting Agreement, including form of Lock-up Agreement. Exhibit 1.1 [?] Shares Ventyx Biosciences, Inc. UNDERWRITING AGREEMENT October [?], 2021 JEFFERIES LLC EVERCORE GROUP L.L.C. PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o EVERCORE GROUP L.L.C. 55 East 52nd Street New York, New York 10055 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota |
|
| October 15, 2021 |
Exhibit 10.12 CONFIDENTIAL MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT (the ?Agreement?) is entered into as of January 17, 2019, (the ?Effective Date?) by and between VENTYX BIOSCIENCES, INC., a corporation organized under the laws of Delaware, having a principal place of business at 662 Encinitas Blvd, Suite 250, Encinitas, CA 92024, USA (?Ventyx?), and BAYSIDE PHARMA, LLC, a corpora |
|
| October 15, 2021 |
Exhibit 10.14 STANDARD MULTI-TENANT OFFICE LEASE - GROSS 1. Basic Provisions (?Basic Provisions?). 1.1 Parties: This Lease (?Lease?), dated for reference purposes only September 15, 2021, is made by and between Chariotta Partners, Inc., a CA corporation and 9310 Towne Centre Drive Harrison-1, LLC, a CA limited, liability company (collectively ?Lessor?) and Ventvx Biosciences, Inc., a CA corporatio |
|
| October 14, 2021 |
October 14, 2021 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F St NE Washington, D. |
|
| October 14, 2021 |
As filed with the Securities and Exchange Commission on October 14, 2021. Table of Contents As filed with the Securities and Exchange Commission on October 14, 2021. |
|
| October 5, 2021 |
Wilson Sonsini Goodrich & Rosati Professional Corporation 12235 El Camino Real San Diego, California 92130 O: 858. |
|
| September 29, 2021 |
DRSLTR 1 filename1.htm September 29, 2021 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F St NE Washington, D.C. 20549 Attention: Li Xiao Jeanne Baker Deanna Virginio Suzanne Hayes Re: Ventyx Biosciences, Inc. Draft Registration Statement on Form S-1 Submitted August 20, 2021 CIK No. 0001851194 Ladies and Gentlemen: On behalf |
|
| September 29, 2021 |
Second Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VENTYX BIOSCIENCES, INC. SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VENTYX BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Ventyx Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation |
|
| September 29, 2021 |
Exhibit 10.10 May 21, 2021 Via email William R. White [***] Email: [***] Tel: [***] Re:Ventyx Biosciences, Inc. Board of Directors Dear Mr. White: On behalf of Ventyx Biosciences, Inc. (the ?Company?), we would like to invite you to join the Company?s Board of Directors (the ?Board?) as a member of the Board. Once you accept this invitation, we anticipate the Board moving quickly to formalize your |
|
| September 29, 2021 |
Exhibit 10.2 VENTYX BIOSCIENCES, INC. 2019 EQUITY INCENTIVE PLAN 1.Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Stock Optio |
|
| September 29, 2021 |
Subsidiaries of the Registrant. Exhibit 21.1 Ventyx Biosciences, Inc. List of Subsidiaries Name Jurisdiction of Organization Oppilan Pharma, Inc. Delaware Oppilan Pharma, Ltd. United Kingdom Zomagen Biosciences Belgium BV Belgium Zomagen Biosciences Ltd. United Kingdom |
|
| September 29, 2021 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT between VIMALAN BIOSCIENCES, INC. and VENTYX BIOSCIENCES, INC. dated as of February 7, 2019 1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this ?Agreement?), dated as of February 7, 2019 (the ?Effective Date?), is entered into between Vimalan Biosciences, Inc., a Delaware corporation (?Seller?) and Ventyx Biosciences, Inc., a Delaware corporation (?B |
|
| September 29, 2021 |
Exhibit 2.2 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (the ?Agreement?) is made as of February 26, 2021, by and among Ventyx Biosciences, Inc., a Delaware corporation (the ?Purchaser?), Zomagen Biosciences Ltd., a private company limited by shares, incorporated and registered in England and Wales with company number 11475190 whose registered office is at 125 Wood Street, London, EC2V |
|
| September 29, 2021 |
Exhibit 2.3 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (the ?Agreement?) is made as of February 26, 2021, by and among Ventyx Biosciences, Inc., a Delaware corporation (the ?Purchaser?), Oppilan Pharma Ltd., a private company limited by shares, incorporated and registered in England and Wales with company number 09610773 whose registered office is at St. John?s Innovation Centre, Cowle |
|
| September 29, 2021 |
Amended and Restated Bylaws of the Registrant, as currently in effect. Exhibit 3.3 BYLAWS OF VENTYX BIOSCIENCES, INC. Adopted November 21, 2018 TABLE OF CONTENTS Page ARTICLE I ? MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders? Meetings 1 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 2 1.9 Stockholder Action by Written Consent Without a Meeting 3 1.10 Record D |
|
| September 29, 2021 |
Exhibit 10.1 VENTYX BIOSCIENCES, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is dated as of [insert date], and is between Ventyx Biosciences, Inc., a Delaware corporation (the ?Company?), and [insert name of indemnitee] (?Indemnitee?). RECITALS A.Indemnitee?s service to the Company substantially benefits the Company. B.Individuals are reluctant to serve as dire |
|
| September 29, 2021 |
Exhibit 10.9 May 14, 2020 Sheila Gujrathi [***] Dear Sheila, On behalf of Ventyx Biosciences, Inc. (the ?Company?), I am extremely pleased to invite you to join the Company as Executive Chairperson of the Company through the ninetieth (90th) day following the closing of the Company?s IPO (as defined below) (?Executive Chairperson?) and as a member of the Company?s board of directors (the ?Board?), |
|
| September 29, 2021 |
Exhibit 4.1 VENTYX BIOSCIENCES, INC. AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT September 9, 2021 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 5 2.1 Demand Registration 5 2.2 Company Registration 6 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 8 2.5 Furnish Information 9 2.6 Expenses of Registration 9 2.7 Delay of Registration 9 2.8 Indemnification 9 2.9 Re |
|
| September 29, 2021 |
Powers of Attorney (included in page II-7 to this registration statement). S-1 1 vtyx-s1.htm S-1 As filed with the Securities and Exchange Commission on September 29, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑1 REGISTRATION STATEMENT Under The Securities Act of 1933 VENTYX BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 83-2996852 (State or other jurisdiction of incorp |
|
| August 20, 2021 |
As confidentially submitted with the Securities and Exchange Commission on August 20, 2021. |
